Bli medlem
Bli medlem

Du är här

2019-02-28

ExpreS2ion Biotechnologies: ExpreS2ion Biotech Holding AB: Publication of financial report for January - December 2018

ExpreS2ion Biotech Holding AB ("ExpreS2ion") hereby publishes
financial report for the period of January - December 2018. The
report is available as an attached document to this press release and
on the Company's website (www.expres2ionbio.com). Below is a summary
of the report.

CEO Dr. Steen Klysner comments

"In 2018 we focused on the continued expansion of our core platform by
developing and including new technologies, as well as strengthening
our joint venture AdaptVac. We have succeeded well with these
activities and have documented good progress in a number of existing
and new projects at the same time. This investment was however
reflected negatively in our revenues that were below what we
expected. Looking forward, we now expect to see the service business
gain momentum as an isolated business approaching a sustainable
plateau in 2019. Beside this, an increasing and highly exciting part
of our activities will target the development of new and existing
assets in partnerships and joint ventures, based on our optimised
proprietary discovery platform."

Q4 (2018-10-01 to 2018-12-31)

· Group turnover amounted to 1,434 (1,823) KSEK.
· Result after financial items amounted to -6,104 (-4,124) KSEK.
· Net income amounted to -5,585 (-3,135) KSEK.
· Net income per share* amounted to -0.47 (-0.33) SEK.

The fiscal year 2018 (2018-01-01 to 2018-12-31)

· Group turnover amounted to 8,868 (9,795) KSEK.
· Result after financial items amounted to -18,853 (-11,750) KSEK.
· Net income amounted to -16,822 (-9,835) KSEK.
· Net income per share* amounted to -1.46 (-1.10) SEK.
· Cash flow from operating activities amounted to -12,879 (-8,608)
KSEK

· Equity ratio** amounted to 39.6 (39.1) %.
· Cash and cash equivalents amounted to 6,255 (1,508) KSEK.
Numbers in parenthesis are the numbers from the same period in 2017.

*The Group's net income per share: the net income for the period
divided by 11,541,664, which is the average number of shares for the
whole period. The average number of shares for the fourth quarter was
12,002,015. The total number of shares in ExpreS2ion Biotech Holding
AB was 12,002,015 shares per 2018-12-31.

**Equity ratio: Shareholder's equity divided by total capital.

Significant events during Q4 2018

· On October 3, the Company announced that a recently published
scientific article in Nature Communications on the Pfs48/45 malaria
vaccine candidate adds further evidence to support that the ExpreS2
platform is an excellent tool for producing transmission blocking
malaria vaccines.

· On October 31, the Company announced that the Jenner Institute of
the University of Oxford had presented positive results from its
Phase I/IIa clinical studies with their RH5.1 blood-stage malaria
vaccine at a scientific meeting in New Orleans. The vaccine,
developed and manufactured using the ExpreS2 platform, was shown to
be safe and it is the first vaccine to demonstrate a reduction in the
parasite multiplication rate following a blood-stage controlled human
malaria infection. This is a very important milestone in a
longstanding collaboration with The Jenner institute of Oxford and as
stated by Professor Dr. Simon Draper, Leader of the Jenner
Institute's Blood-Stage Malaria Vaccine Group, "the encouraging
results from this RH5.1 Phase I/IIa malaria study are in line with
our preclinical findings and form a solid foundation on which to
build the next steps in our blood-stage malaria vaccine clinical
programme. We are grateful to ExpreS2ion for providing the enabling
ExpreS2 development and production platform, and their contribution
to the project as a whole."

· On December 12, ExpreS2ion announced the publication of the first
visual image of the molecular 'key' the deadliest malaria parasite
uses to enter human blood cells in the scientific journal Nature. The
publication was authored by an international team, including
scientists from ExpreS2ion, led by the Walter and Eliza Hall
Institute of Medical Research ("WEHI"). This breakthrough will
contribute to the development of vaccines based on a patent co-owned
equally by WEHI and ExpreS2ion.

· On December 20, ExpreS2ion announced that the Company's joint
venture AdaptVac has received DKK 2.2 million (SEK 3.2 million) in
funding from the Danish Innovation Foundation for two new vaccine
development projects: cardiovascular disease in humans and HER2+
breast cancer in dogs.

Significant events after the end of the period

· On January 10, 2019, ExpreS2ion announced that the placental
malaria vaccine (PlacMalVac) consortium, of which ExpreS2ion is part,
has announced successful phase I clinical study results. The PAMVAC
vaccine, manufactured using the ExpreS2 platform, was demonstrated to
be safe, well-tolerated and to elicit specific antibody responses in
all participants.

· On February 19, 2019, ExpreS2ion announced that its joint venture
AdaptVac has been awarded approx. SEK 3.6 million by the Danish
Innovation Foundation for its participation in a vaccine project
aimed at preventing post-weaning diarrhoea, a major cause of
antibiotic use in the swine industry.

A complete summary of significant events during 2018 is available in
the attached financial report.

Certified Adviser

Sedermera Fondkommission

E-mail: CA@sedermera.se

Telephone: +46 40-615 14 10

For further information about ExpreS2ion Biotech Holding AB, please
contact:

Dr. Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com

This press release contains information that ExpreS2ion is obligated
to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication through the agency of the
contact person set out above on February 28, 2019.

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of
ExpreS2ion Biotech Holding AB with company register number
559033-3729. The subsidiary has developed a unique proprietary
platform technology, ExpreS2, that can be used for fast and efficient
preclinical and clinical development as well as robust production of
complex proteins for new vaccines and diagnostics. Since the Company
was founded in 2010, it has produced more than 300 proteins and 40
virus-like particles (VLPs) in collaboration with leading research
institutions and companies, demonstrating superior efficiency and
success rates. In addition, ExpreS2ion develops novel VLP based
vaccines through the joint venture AdaptVac ApS which was founded in
2017.

-----------------------------------------------------------
http://news.cision.com/se/expres2ion-biotechnologies/r/expres2ion-biotec...
https://mb.cision.com/Main/14402/2752502/999584.pdf

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.